Halozyme Therapeutics (GB:0J2O)

Halozyme Financial Statements

Halozyme Financial Overview

Halozyme's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Halozyme is scheduled to report earnings on November 8, 2022, and the estimated EPS forecast is $0.40. See an overview of income statement, balance sheet, and cash flow financials.
Mar 22Dec 21Sep 21Jun 21Mar 21
Income Statement
Total Revenue$ 117.28M$ 102.00M$ 115.83M$ 136.46M$ 89.02M
Gross Profit$ 101.36M$ 80.42M$ 97.24M$ 113.44M$ 70.80M
EBIT$ 76.17M$ 56.87M$ 75.86M$ 93.27M$ 30.05M
EBITDA$ 76.95M$ 57.64M$ 76.61M$ 94.00M$ 30.79M
Net Income Common Stockholders$ 60.11M$ 66.77M$ 216.59M$ 91.46M$ 27.89M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 346.71M$ 368.01M$ 740.92M$ 755.31M$ 764.31M
Total Assets$ 1.16B$ 1.10B$ 1.19B$ 1.03B$ 966.58M
Total Debt$ 482.67M$ 873.90M$ 874.82M$ 875.87M$ 876.80M
Net Debt$ 135.97M$ 505.88M$ 133.90M$ 120.56M$ 112.50M
Total Liabilities$ 901.99M$ 907.48M$ 903.75M$ 906.12M$ 898.99M
Stockholders Equity$ 67.59M$ 98.99M$ 119.75M$ 151.05M$ 196.95M
Cash Flow
Free Cash Flow$ 47.31M$ 82.36M$ 121.24M$ 36.36M$ 58.03M
Operating Cash Flow$ 47.80M$ 82.52M$ 121.74M$ 36.89M$ 58.30M
Investing Cash Flow$ -49.30M$ -299.47M$ -16.95M$ -44.62M$ -45.25M
Financing Cash Flow$ 624.00K$ -156.01M$ -60.07M$ -44.76M$ 338.70M
Currency in USD

Halozyme Earnings and Revenue History

Halozyme Debt to Assets

Halozyme Cash Flow

Halozyme Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis